



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 31/485, 9/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/23079</p> <p>(43) International Publication Date: 27 April 2000 (27.04.00)</p>
<p>(21) International Application Number: PCT/EP99/07595</p> <p>(22) International Filing Date: 11 October 1999 (11.10.99)</p> <p>(30) Priority Data: MI98A002222 16 October 1998 (16.10.98) IT</p> <p>(71) Applicant (for all designated States except US): FARMA- CEUTICI FORMENTI S.P.A. [IT/IT]; Via Correggio, 45, I-20149 Milano (IT).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): VALENTI, Mauro [IT/IT]; Via di Vittorio, 2, I-21040 Origgio (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja Srl, Via Rossini, 8, I-20122 Milano (IT).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORPHIN</p> <p>(57) Abstract</p> <p>An oral pharmaceutical composition containing buprenorphin or a pharmaceutically acceptable salt thereof as the active ingredient, characterised in that it contains a pharmaceutically acceptable antioxidant.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING BUPRENORPHIN

The present invention relates to oral pharmaceutical compositions, in particular to compositions containing buprenorphin as active ingredient. These compositions are particularly stable with respect to the commercially available products.

5 Background of the invention.

Buprenorphin, namely 21 -cyclopropyl-7 α -(2-hydroxy-3,3-dimethyl-2butyl)-6,14-endo-ethano-6,7,8,18-tetrahydroripavine, is a morphine alkaloid with analgesic properties. Its preparation is disclosed in US 3433791, for a review see J.W.Lewis in Advan. Biochem. Psychopharmacol. Vol. 8, M.C. Braude et al. eds. (Raven Press, New York, 1974).

This analgesic is marketed under the trade marks TEMGESIC, BUPRENEX, LEPETAN.

Sublingual tablets containing buprenorphin as active ingredient, for example TEMGESIC 0.2 and 0.4 mg, show the presence of products from the degradation of the active ingredient.

15 Disclosure of the Invention

It has now been found that the addition of pharmaceutically acceptable antioxidants gives oral pharmaceutical compositions, containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient, a particularly good stability, decreasing the formation of the degradation products.

Advantageously, the oral pharmaceutical compositions according to the present invention are more stable than the presently available dosage forms of the state of the art, hence they have a longer shelf-life.

25 Therefore, it is an object of the present invention an oral pharmaceutical composition containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in that it contains a pharmaceutically acceptable antioxidant in addition to conventional vehicles and eccipients.

This and other objects of the present invention will be disclosed in detail, also by means of examples.

Detailed disclosure of the invention

Pharmaceutically acceptable antioxidants are well known to the person skilled in the art and are described in the technical literature forming the general common knowledge. A source of information, for example, can be found in "Remington's Pharmaceutical Sciences Handbook", Mack Pub. N.Y. USA.

A first group of preferred antioxidants comprises ascorbic acid, its salts and esters, Vitamin E, tocopherol and its salts, sodium metabisulphite, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT).

A more preferred group of antioxidants comprises ascorbic acid, sodium metabisulphite, Vitamin E, alpha-lipoic acid.

The most preferred antioxidant is ascorbic acid.

The molar ratio between the antioxidant and buprenorphin is at least 1:1, more preferably 3:1.

The commercial formulations contain magnesium ions due to the presence of magnesium stearate, a well-known lubricant.

It has surprisingly been found that significantly better results are achieved if the presence of magnesium ion is avoided in the formulation of the present invention. Therefore, a further object of the present invention is an oral formulation containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in that it further contains a pharmaceutically acceptable antioxidant and in that the magnesium ion is absent.

In a first embodiment of this further aspect of the invention, magnesium stearate is substituted by another lubricant. Hydrogenated castor oil is a preferred example.

It has further surprisingly been found that significant results are also achieved if the presence of magnesium ion is avoided and the buffer system is changed in the formulation of the present invention. Therefore, a further object of the present invention is an oral formulation containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in

that it further contains a pharmaceutically acceptable antioxidant, in that the magnesium ion is absent and in that the buffer system differs from that of the commercial formulations.

5 In a preferred embodiment of this further aspect of the invention, glycine/hydrochloric acid is the buffer system.

The formulations obtained according to this further aspects of the present invention, are fully satisfactory in view of the stability of the active ingredient, but have a poor external aspect, so that the consumers could not accept them.

10 While searching to improve the stability of the oral formulation, by reducing the amount of degradation products, and maintaining a good external aspect it has surprisingly been found that the elimination of polyvinylpyrrolidone, even keeping magnesium stearate as lubricant, and without changing the buffer system, gives very good results. Therefore, a
15 further aspect of the present invention is an oral pharmaceutical composition containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in that it further contains a pharmaceutically acceptable antioxidant and in that it does not contain polyvinylpyrrolidone.

The present invention applies to oral dosage forms. Oral dosage forms
20 are conventionally known in the art, and no particular disclosure is herein needed, since they can be prepared by resorting to general common knowledge as provided by textbooks, manuals and other technical literature, which are normally available.

25 Examples of oral dosage forms are pills, capsules, tablets, powders, solutions, suspensions and the like. In a preferred embodiment of this invention, oral compositions are in the form of sublingual tablets.

Commercial batches of TEMGESIC having the same quali-quantitative composition were replicated (hereinafter referred to as "FRT") and tested for stability together with a batch of TEMGESIC as available on the market.

30 Stability protocols were designed as outlined in Table 1 below:

TABLE 1

STABILITY PROTOCOLS

	Batch FRT 10097	0.4 mg
	Batch FRT 16097	0.2 mg
5	Batch Temgesic T19501	0.2 mg

1. IN GLASS VIALS

Temperature	7 days	15 days	30 days
25°C + 60% R.H.			X
30°C + 70% R.H.		X	X
40°C + 75% R.H.	X	X	X
50°C	X	X	X

RH = Relative humidity

10 The studies were directed at the determination of the titre of the active ingredient and of the related degradation products.

TABLE 2 shows the results.

TABLE 2

Stability studies in glass vials.

days	Batch 10097 0.4 mg		Batch 16097 0.2 mg		Temgesic Batch T19501 0.2 mg	
	Titre in Buprenor- phin	Total degrada- tion products	Titre in Buprenor- phin	Total degrada- tion products	Titre in Buprenor- phin	Total degrada- tion products
Temperature 25°C + 60% R.H.						
0	99.29%	1.19%	99.40%	1.84%	96.10%	2.97%
30	96.82%	7.22%	97.8%	5.62%	90.45%	7.49%
Temperature 30°C + 70% R.H.						
0	99.29%	1.19%	99.40%	1.84%	96.10%	2.97%
15	94.65%	8.05%	97.57%	5.71%	91.16%	7.97%
30	94.62%	9.42%	97.80%	5.62%	88.16%	10.51%
Temperature 40°C + 75% R.H.						
0	99.29%	1.19%	99.40%	1.84%	96.10%	2.97%
7	98.78%	2.31%	97.78%	3.30%	92.92%	6.10%
15	95.96%	2.82%	94.95%	4.33%	87.42%	8.25%
30	98.28%	3.85%	96.16%	5.43%	86.43%	9.06%
Temperature 50°C						
0	99.29%	1.19%	99.40%	1.84%	96.10%	2.97%
7	89.66%	10.47%	93.54%	7.43%	85.59%	11.44%
15	89.42%	9.97%	95.23%	6.25%	84.71%	10.56%
30	88.88%	11.31%	96.52%	6.69%	77.23%	15.15%

Three batches of buprenorphin tablets were prepared according to the present invention, each batch containing a different pharmaceutically acceptable antioxidant. The compositions of the batches are shown in Table 3 below.

5 The molar ratio antioxidant/buprenorphin is 1/1.

TABLE 3
FORMULATIONS

INGREDIENT NAME	Example 1	Example 2	Example 3
	Vitamin C Batch 23038	Sodium Metabisulphite Batch 24038	Vitamin E Batch 25038
Buprenorphin hydrochloride	0.216 mg	0.216 mg	0.216 mg
Equivalent to Buprenorphin	0.200 mg	0.200 mg	0.200 mg
Antioxidant	0.151 mg	0.163 mg	0.405 mg
Lactose	29.690 mg	29.678 mg	29.436 mg
Maize starch	9.000 mg	9.000 mg	9.000 mg
Mannitol	18.000 mg	18.000 mg	18.000 mg
Polyvinylpyrrolidone	1.200 mg	1.200 mg	1.200 mg
Anhydrous Citric Acid	0.888 mg	0.888 mg	0.888 mg
Sodium Citrate 2H ₂ O	0.405 mg	0.405 mg	0.405 mg
Magnesium Stearate	0.450 mg	0.450 mg	0.450 mg

The batches were tested for stability according to the experimental protocol shown in Table 4 below.

TABLE 4
STABILITY PROTOCOLS
(In glass vials)

5

Temperature	0.5 Months	1. Month	2.0 Months	3.0 Months
25°C + 60% R.H.		X	X	X
40°C + 75% R.H.	X	X	X	X
50°C	X		X	X
80°C	X	X		

The results are shown in tables 5-7 below.

TABLE 5

Buprenorphin tablets 0.2 mg - Batch 23038 with Vit. C 1/1

Conditions	Time	Titre in Buprenorphin	Total Degradation products
	Initial	101.00%	< 0.10%
25°C + 60% R.H.	1 month	100.63%	0.11%
25°C + 60% R.H.	2 months	100.90%	0.57%
25°C + 60% R.H.	3 months	99.21%	0.48%
40°C + 75% R.H.	0.5 months	102.54%	0.35%
40°C + 75% R.H.	1 month	100.15%	0.57%
40°C + 75% R.H.	2 months	101.06%	0.73%
40°C + 75% R.H.	3 months	98.68%	0.78%
50°C	0.5 months	102.59%	0.69%
50°C	2 months	102.23%	0.83%
50°C	3 months	102.54%	1.12%
80°C	0.5 months	97.73%	2.44%
80°C	1 month	93.34%	3.76%

TABLE 6

Buprenorphin tablets 0.2 mg - Batch 24038 with Metabis. 1/1

Conditions	Time	Titre in Buprenorphin	Total Degradation products
	Initial	100.43%	0.11%
25°C + 60% R.H	1 month	99.60%	0.78%
25°C + 60% R.H.	2 months	100.91%	1.55%
25°C + 60% R.H.	3 months	98.06%	2.00%
40°C + 75% R.H.	0.5 months	101.10%	1.13%
40°C + 75% R.H	1 month	99.79%	3.12%
40°C + 75% R.H.	2 months	99.78%	3.05%
40°C + 75% R.H.	3 months	98.41%	3.83%
50°C	0.5 months	101.42%	1.47%
50°C	2 months	99.06%	2.77%
50°C	3 months	99.62%	2.83%
80°C	0.5 months	93.48%	4.61%
80°C	1 month	90.54%	11.28%

TABLE 7

Buprenorphin tablets 0.2 mg - Batch 25038 with Vit. E 1/1

Conditions	Time	Titre in Buprenorphin	Total Degradation Products
	Initial	98.83	0.09%
25°C + 60% R.H.	1 month	100.14%	0.64%
25°C + 60% R.H.	2 months	98.86%	1.85%
25°C + 60% R.H.	3 months	98.90%	2.89%
40°C + 75% R.H.	0.5 months	100.20%	1.20%
40°C + 75% R.H.	1 month	98.35%	1.74%
40°C + 75% R.H.	2 months	102.64%	4.66%
40°C + 75% R.H.	3 months	95.40%	5.81%
50°C	0.5 months	98.41%	2.64%
50°C	2 months	95.78%	5.35%
50°C	3 months	95.48%	5.34%
80°C	0.5 months	94.60%	4.18%
80°C	1 month	89.49%	4.81%

The compositions according to the present invention are more stable than those commercially available and those replicated by Formenti.

5 It shall be noted that ascorbic acid gives very good results. The total amount of degradation products is by far lower than the one found in commercial products, even in the worst conditions of experimental protocol. Sodium metabisulphite and Vitamin E give the same results.

10 Another embodiment of the present invention is disclosed in the following. Three batches were prepared according to the experimental design of Table 8 below. Ascorbic acid is used in a molar ratio of 3/1 with respect to the active ingredient. In a second batch, magnesium ion is eliminated and an alternative lubricant is used. In a third batch, together the alternative lubricant, also a different buffer system is used.

TABLE 8
FORMULATIONS

INGREDIENTS	Example 4 Batch 08048	Example 5 Batch 09048	Example 6 Batch10048
Buprenorphin Hydrochloride	0.216 mg	0.216 mg	0.216 mg
Equivalent to Buprenorphin	0.200 mg	0.200 mg	0.200 mg
Vitamin C	0.453 mg	0.453 mg	0.453 mg
Lactose	29.388 mg	29.238 mg	29.379 mg
Maize starch	9.000 mg	9.000 mg	9.000 mg
Mannitol	18.000 mg	18.000 mg	18.000 mg
Polyvinylpyrrolidone	1.200 mg	1.200 mg	1.200 mg
Anhydrous Citric Acid	0.888 mg	0.888 mg	= = =
Sodium Citrate. 2H ₂ O	0.405 mg	0.405 mg	= = =
Magnesium Stearate	0.450 mg	= = =	= = =
Hydrogenated castor oil	= = =	0.600 mg	0.600 mg
Glycine/Hydrochloric acid	= = =	= = =	0.955 mg
Hydrochloric Acid to pH 3.3	= = =	= = =	2 ml

Stability protocols are the same as the former tests.

The results are shown in tables 9-11 below.

TABLE 9

Buprenorphin tablets 0.2 mg - Batch 23038 with Vit. C 1/1

5

Conditions	Time	Titre in Buprenorphin	Total Degradation Products
	Initial	100.93%	0.16%
25°C + 60% R.H.	1 month	99.30%	0.31%
25°C + 60% R.H.	2 months	103.23%	0.47%
25°C + 60% R.H.	3 months	102.17%	0.47%
40°C + 75% R.H.	0.5 months	102.98%	0.21%
40°C + 75% R.H.	1 month	103.35%	0.51%
40°C + 75% R.H.	2 months	102.52%	0.52%
40°C + 75% R.H.	3 months	103.80%	0.52%
50°C	0.5 months	103.10%	0.21%
50°C	2 months	103.41%	0.54%
50°C	3 months	100.74%	0.66%
80°C	0.5 months	97.93%	2.01%
80°C	1 month	92.02%	4.63%

TABLE 10

Buprenorphin tablets 0.2 mg - Batch 09048 with Vit. C 3/1

Conditions	Time	Titre in Buprenorphin	Total degradation products
	Initial	100.81%	0.16%
25°C + 60% R.H.	1 month	101.35%	0.40%
25°C + 60% R.H.	2 months	101.89%	0.32%
25°C + 60% R.H.	3 months	104.38%	0.42%
40°C + 75% R.H.	0.5 months	102.73%	0.16%
40°C + 75% R.H.	1 month	101.22%	0.32%
40°C + 75% R.H.	2 months	102.43%	0.32%
40°C + 75% R.H.	3 months	103.45%	0.44%
50°C	0.5 months	101.62%	0.16%
50°C	1 month	100.86%	0.64%
50°C	2 months	101.88%	0.49%
50°C	3 months	103.38%	0.56%
80°C	0.5 months	98.58%	1.74%
80°C	1 month	92.72%	4.70%

TABLE 11

Buprenorphin tablets 0.2 mg - Batch 10048 with Vit. C 1/1

Glycine/hydrochloride acid and hydrogenated castor oil

Conditions	Time	Titre in Buprenorphin	Total Degradation products
	Initial	101.21%	0.15%
25°C + 60% R.H.	1 month	101.39%	0.49%
25°C + 60% R.H.	2 months	101.22%	0.30%
25°C + 60% R.H.	3 months	101.36%	0.29%
40°C + 75% R.H.	0.5 months	103.27%	0.18%
40°C + 75% R.H.	1 month	100.44%	0.90%
40°C + 75% R.H.	2 months	101.72%	0.32%
40°C + 75% R.H.	3 months	104.68%	0.29%
50°C	0.5 months	101.96%	0.25%
50°C	1 month	99.20%	0.51%
50°C	2 months	101.78%	0.41%
50°C	3 months	100.01%	0.54%
80°C	0.5 months	100.00%	1.41%
80°C	1 month	94.62%	5.25%

The compositions according to this embodiment of the present invention have the same stability of those of the first embodiment at r.t., but the amount of degradation products is decreased. Advantageously, this second embodiment gives a higher stability at more severe conditions.

5 It shall be noted that the elimination of magnesium ions still improves stability. Changing buffer system also confirms the trend to good results.

Another embodiment of the present invention comprises the elimination of polyvinylpyrrolidone from the formulation.

10 Buprenorphin sublingual tablets were prepared according to the following composition:

	Example 7	Example 8
INGREDIENT	Buprenorphin 0.2 mg	Buprenorphin 0.4 mg
Buprenorphin Hydrochloride	0.216 mg	0.432 mg
Equivalent to Buprenorphin	0.200 mg	0.400 mg
Vitamin C	0.453 mg	0.906 mg
Lactose	30.588 mg	29.919 mg
Maize starch	9.000 mg	9.000 mg
Mannitol	18.000 mg	18.000 mg
Citric acid hydrochloride	0.888 mg	0.888 mg
Sodium Citrate . 2H ₂ O	0.405 mg	0.405 mg
Magnesium Stearate	0.450 mg	0.450 mg

The tablets comply with the analytical requirements.

TABLE 12

Assay	References	Limits	Results	Results
			Buprenorphin tablets 0,2 mg	Buprenorphin tablets 0,4 mg
Appearance		Must comply	Complies	Complies
Buprenorphin identification		Must comply	Positive	Positive
Average weight	Eur. Ph., III ed.	60 mg/tablet	59.58 mg	59.85 mg
Weight uniformity	Eur. Ph., III ed.	Must comply	Complies	Complies
Content uniformity	Eur. Ph., III ed.	Must comply	Complies	Complies
Water	Eur. Ph., III ed.	≤ 5.0%	3.87%	350%
Disintegration Test	Eur. Ph., III ed.	≤ 5 minutes	≤ 1 minutes	≤ 1 minutes
Dissolution Test	Eur. Ph., III ed.			
- After 2 minutes		≥ 60.0%	92.2%	93,2%
- After 4 minutes		≥ 80.0%	94.0%	95,4%
Degradation products		≤ 2.0% total	≤ 0.1%	≤ 0.1%
Titre		95.0 - 105.0%	100.62%	100.62%

CLAIMS

1. An oral pharmaceutical composition containing buprenorphin or a pharmaceutically acceptable salt thereof as active ingredient characterised in that it further contains a pharmaceutically acceptable antioxidant.
- 5 2. An oral pharmaceutical composition according to claim 1, wherein said antioxidant is selected from the group consisting of: ascorbic acid, its salts and esters, Vitamin E, tocopherol and its salts, sodium metabisulphite, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), alpha-lipoic acid.
- 10 3. An oral pharmaceutical composition according to claim 2, wherein said antioxidant is selected from the group consisting of: ascorbic acid, its salts and esters, Vitamin E, sodium metabisulphite.
4. An oral pharmaceutical composition according to claim 3, wherein said antioxidant is ascorbic acid, its salts and esters.
- 15 5. An oral pharmaceutical composition according to claim 1, wherein the molar ratio between said antioxidant and buprenorphin is at least 1:1, more preferably 3:1.
6. An oral pharmaceutical composition according to any one of claims 1-5, wherein the magnesium ion is absent.
- 20 7. An oral pharmaceutical composition according to claim 6, wherein hydrogenated castor oil is the lubricant.
8. An oral pharmaceutical composition according to any one of claims 1-7, wherein glycine/hydrochloric acid is the buffer system.
9. An oral pharmaceutical composition according to any one of claims 1-8, wherein polyvinylpyrrolidone is absent.
- 25 10. An oral pharmaceutical composition according to any one of claims 1-9 in the form of a sublingual tablet.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07595

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/485 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 33566 A (ALZA) 18 September 1997 (1997-09-18) claims 8,9,12,13	1-4
A	EP 0 180 303 A (AMERICAN HOME PRODUCTS) 7 May 1986 (1986-05-07) claims tables	1-4

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 January 2000

Date of mailing of the international search report

27/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/07595

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9733566 A	18-09-1997	AU 2059297 A	01-10-1997
		EP 0914097 A	12-05-1999
		US 5866164 A	02-02-1999

EP 180303 A	07-05-1986	AT 41602 T	15-04-1989
		AU 572689 B	12-05-1988
		AU 4713685 A	10-04-1986
		CA 1251402 A	21-03-1989
		DK 438785 A, B,	29-03-1986
		GB 2165149 A, B	09-04-1986
		HK 19990 A	23-03-1990
		HU 39359 A	29-09-1986
		IE 58139 B	14-07-1993
		IL 76393 A	30-06-1988
		JP 1896970 C	23-01-1995
		JP 6021060 B	23-03-1994
		JP 61085314 A	30-04-1986
		KR 8900905 B	13-04-1989
		NZ 213573 A	28-07-1988
		PH 20498 A	21-01-1987
		SG 71489 G	02-03-1990
US 4605671 A	12-08-1986		
